Skip to Content

NeoProfen Approval History

  • FDA approved: Yes (First approved April 13th, 2006)
  • Brand name: NeoProfen
  • Generic name: ibuprofen lysine
  • Dosage form: Injection
  • Company: Farmacon-IL, LLC
  • Treatment for: Patent Ductus Arteriosus

NeoProfen is an intravenous formulation of ibuprofen lysine indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants, who are no more than 32 weeks gestational age when usual medical management is ineffective.

Development History and FDA Approval Process for NeoProfen

DateArticle
Apr 13, 2006Approval NeoProfen Approved - Farmacon-IL, LLC - Treatment for Patent Ductus Arteriosus

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide